 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced that the U.S. Food and Drug Administration FDA has issued a complete response letter CRL for its Abbreviated New Drug Application ANDA for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA within 30 days. Importantly, Eagle has completed an extensive amount of developmental work and continu 